Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand

[1]  A. Nanbo,et al.  Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand. , 2023, Lancet. Infectious Diseases (Print).

[2]  Mun-Keat Looi.  Covid-19: Hospital admissions rise in England amid fears of new variant and waning immunity , 2023, British medical journal.

[3]  V. Vasiliou,et al.  COVID-19 annual update: a narrative review , 2023, Human Genomics.

[4]  F. Paolucci,et al.  Are we past the COVID-19 Pandemic? Insights from Singapore , 2023, Health Policy and Technology.

[5]  D. Sano,et al.  COVID-19 monitoring with sparse sampling of sewered and non-sewered wastewater in urban and rural communities , 2023, iScience.

[6]  J. Zarocostas.  With the COVID-19 PHEIC over, what next? , 2023, The Lancet.

[7]  M. Keeling,et al.  Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic , 2022, Nature Medicine.

[8]  Charin Modchang,et al.  Individual-based modeling reveals that the COVID-19 isolation period can be shortened by community vaccination , 2022, Scientific Reports.

[9]  S. Merler,et al.  Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply , 2022, Scientific Reports.

[10]  Yacob T. Tesfaldet,et al.  The secondary outcome of public health measures amidst the COVID-19 pandemic in the spread of other respiratory infectious diseases in Thailand , 2022, Travel Medicine and Infectious Disease.

[11]  E. Herzel,et al.  SARS-CoV-2 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: a Retrospective Cohort Study. , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Carl A. B. Pearson,et al.  Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis , 2022, The Lancet Regional Health - Europe.

[13]  Y. Poovorawan,et al.  Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data , 2022, Vaccine.

[14]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[15]  Y. Poovorawan,et al.  Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study , 2022, Human vaccines & immunotherapeutics.

[16]  Charin Modchang,et al.  Estimation of Excess All-Cause Mortality Due to COVID-19 in Thailand , 2022, medRxiv.

[17]  A. M. Kilpatrick,et al.  Estimates of reduced vaccine effectiveness against hospitalization, infection, transmission and symptomatic disease of a new SARS-CoV-2 variant, Omicron (B.1.1.529), using neutralizing antibody titers , 2021, medRxiv.

[18]  Jue Liu,et al.  Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis , 2021, Infectious Diseases of Poverty.

[19]  J. Kunno,et al.  Comparison of Different Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand , 2021, Advances in preventive medicine.

[20]  S. Truelove,et al.  A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease , 2021, medRxiv.

[21]  C. Sagastizábal,et al.  Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions , 2021, Proceedings of the National Academy of Sciences.

[22]  Charin Modchang,et al.  Southeast Asia is an emerging hotspot for COVID-19 , 2021, Nature Medicine.

[23]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[24]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[25]  Hannah Ritchie,et al.  Author Correction: A global database of COVID-19 vaccinations , 2021, Nature human behaviour.

[26]  J. Schiffer,et al.  Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination , 2021, Nature Communications.

[27]  A. Sheikh,et al.  SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness , 2021, The Lancet.

[28]  Charin Modchang,et al.  Reconstruction of the transmission dynamics of the first COVID-19 epidemic wave in Thailand , 2021, Scientific Reports.

[29]  Christopher S. Tang,et al.  Managing two‐dose COVID‐19 vaccine rollouts with limited supply: Operations strategies for distributing time‐sensitive resources , 2021, Production and operations management.

[30]  A. Marathe,et al.  Prioritizing allocation of COVID-19 vaccines based on social contacts increases vaccination effectiveness , 2021, medRxiv.

[31]  E. Shim.  Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea , 2021, Journal of clinical medicine.

[32]  V. P. Boñgolan,et al.  COVID-19 Agent-Based Model with Multi-objective Optimization for Vaccine Distribution , 2021, 2101.11400.

[33]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[34]  Michael R. Springborn,et al.  Dynamic Prioritization of COVID-19 Vaccines When Social Distancing is Limited for Essential Workers , 2020, Proceedings of the National Academy of Sciences.

[35]  D. Larremore,et al.  Model-informed COVID-19 vaccine prioritization strategies by age and serostatus , 2020, Science.

[36]  Andrew T. Levin,et al.  Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications , 2020, European Journal of Epidemiology.

[37]  T. Stadler,et al.  Practical considerations for measuring the effective reproductive number, Rt , 2020, medRxiv.

[38]  P. Auewarakul,et al.  Reduction in effective reproduction number of COVID-19 is higher in countries employing active case detection with prompt isolation , 2020, Journal of travel medicine.

[39]  M. Roser,et al.  Coronavirus Pandemic (COVID-19) , 2020 .

[40]  N. Linton,et al.  Serial interval of novel coronavirus (COVID-19) infections , 2020, International Journal of Infectious Diseases.

[41]  Mark Jit,et al.  Projecting social contact matrices in 152 countries using contact surveys and demographic data , 2017, PLoS Comput. Biol..

[42]  C. Fraser,et al.  A New Framework and Software to Estimate Time-Varying Reproduction Numbers During Epidemics , 2013, American journal of epidemiology.